Physician profile
Sunil Patel
NPI 1972679942
$5,509.05
in general payments reported to CMS, 2019-2025
36 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $402 · 2021: $351 · 2022: $844 · 2023: $1,042 · 2024: $841 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $946.93 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $919.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $651.49 | 2019-2025 | Airsupra, Lokelma |
| Novo Nordisk INC | $353.95 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $292.73 | 2019-2024 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $286.10 | 2022-2025 | Rexulti, Abilify Maintena |
| Phathom Pharmaceuticals, INC. | $246.33 | 2025 | Voquezna |
| Amgen INC. | $197.72 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.62 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $160.06 | 2024-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $150.31 | 2019-2024 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $142.50 | 2019 | |
| Intra-Sana Laboratories | $128.20 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Genzyme Corporation | $115.37 | 2023 | |
| Sanofi-Aventis U.S. LLC | $90.11 | 2024-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84.21 | 2019-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $77.80 | 2019-2025 | |
| Lundbeck LLC | $54.94 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $53.95 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $38.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.80 | 2023-2025 | |
| Horizon Therapeutics Plc | $34.55 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.56 | 2022 | |
| Alkermes, INC. | $29.38 | 2023 | Lybalvi |
| Allergan, INC. | $28.99 | 2020 | |
| Neurocrine Biosciences, INC. | $23.15 | 2025 | |
| Janssen Biotech, INC. | $22.38 | 2019 | |
| Shield Therapeutics INC | $19.39 | 2025 | |
| Dexcom, INC. | $18.78 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.67 | 2022 | |
| Dynavax Technologies Corporation | $14.03 | 2023 | Heplisav-B |
| Neurelis, INC. | $13.74 | 2023 | Valtoco |
| Kowa Pharmaceuticals America, INC. | $13.61 | 2025 | Zoryve |
| Corcept Therapeutics | $13.58 | 2025 | Korlym |
| Amarin Pharma, INC. | $12.74 | 2023 | |
| Acadia Pharmaceuticals INC | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.